Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole

Clinical Pharmacokinetics

Volumn 49, Issue 1, 2010, Pages 53-66

  Lehr, Thorsten ^a,c   Staab, Alexander ^b   Trommeshauser, Dirk ^b   Schaefer, Hans Guenter ^b   Kloft, Charlotte ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; ITRACONAZOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TESOFENSINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; ENZYME INHIBITION; EVENING DOSAGE; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; CONTROLLED CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS;

EID: 72249107301     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317210-000000000-00000     Document Type: Article

References (34)

1. Marroum PJ, Uppoor RS, Parmelee T, et al. In vivo drugs-drug interaction studies: a survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther 2000; 68: 280-285
2. Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001; 31: 499-538
3. US FDA Center for Drug Evaluation and Research [CDER]. Guidance for industry: in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. Rockville (MD): CDER, 1999 Nov [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM072119.pdf [Accessed 2009 Aug 4]
4. European Medicines Agency [EMEA] Committee for Proprietary Medicinal Products. Note for guidance on the investigation of drug interactions. London: EMEA, 1997 Dec 17 [online]. Available from URL: http://www. emea.europa.eu/pdfs/ human/ewp/056095en.pdf [Accessed 2009 Aug 4]
5. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-469
6. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999; 39: 1006-1014
7. Astrup A, Meier DH, Mikkelsen BO, et al. Weight loss produced by tesofen-sine in patients with Parkinson's or Alzheimer's disease. Obesity 2008; 16: 1363-1369
8. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9653): 1906-1913
9. Thatte U. NS-2330 NeuroSearch. Curr Opin Investig Drugs 2001; 2: 1592-1594
10. Lehr T, Staab A, Tillmann C, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007; 64: 36-48
11. Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacoki-netic-pharmacodynamic modelling approach. Br J Pharmacol 2008; 153: 164-174
12. Van Cutsem J, Van Gerven F, Van de Ven MA. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984; 26: 527-534
13. Isoherranen N, Thummel KE, Kunze KL, et al. Role of itraconazole meta-bolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121-1131
14. Holford NHG, Monteleone JPR, Kimko HC, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209-234
15. Janssen-Cilag GmbH. Sempera Kapseln: Fachinformation. Neuss: Janssen-Cilag, 2001 Apr 1
16. World Medical Association declaration of Helsinki. Recommendations guid-ing physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926
17. European Medicines Agency [EMEA]. Note for guidance on good clinical practice (CPMP/ICH/135/95). Step 5: consolidated guideline, including post step 4 errata. London: EMEA, 1996 May 1
18. Beal SL, Sheiner LB. NONMEM® user's guide: conditional estimation methods. San Francisco (CA): University of California, 1998
19. Akaike H. Canonical correlation analysis of time series and the use of an information criterion. In: Mehra RK, Lambert JC, editors. System identification: advances and case studies. New York: Academic Press, 1976: 27-96
20. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974; 19: 716-723
21. Jonsson EN, Karlsson MO. Xpose: an S-Plus based population pharmacoki-netic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64
22. Koks CHW, Huitema ADR, Beijnen JH, et al. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Ther Drug Monit 2003; 25: 229-233
23. Parke J, Holford NHG, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29
24. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-495
25. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94
26. Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Phar 2008; 35:185-202
27. Macey RI, Oster GF. Berkeley Madonna: modeling and analysis of dynamic systems [online]. Available from URL: http://www.berkeleymadonna.com/ index.html [Accessed 2009 Nov 20]
28. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharmaceut Res 2002; 19: 1835-1840
29. Waterhouse TH, Redmann S, Duffull SB, et al. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn 2005; 32: 521-545
30. Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63: 438-450
31. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099-1114
32. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-1313
33. Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itra-conazole metabolism in vitro and in vivo. Drug Metab Dispos 2006; 34: 583-590
34. US FDA Center for Drug Evalution and Research [CDER]. Guidance for industry: drug metabolism/drug interaction studies in the drug development process, studies in vitro. Rockville (MD): CDER, 1997 Apr [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM072104.pdf [Accessed 2009 Aug 4]